ArticleFrontiers in oncology2025

Ivonescimab combined with chemotherapy shows promising efficacy in an ALK fusion-positive lung adenocarcinoma patient with ALK-TKI resistance: a case report.

Meiyuan Lin et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.